# Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.

> **NCT03697226** · PHASE1 · COMPLETED · sponsor: **Antiva Biosciences** · enrollment: 8 (actual)

## Conditions studied

- HSIL of Cervix
- HSIL, High Grade Squamous Intraepithelial Lesions
- High-Grade Cervical Intraepithelial Neoplasia
- Human Papilloma Virus
- HIV Negative
- Cervical Cancer
- CIN - Cervical Intraepithelial Neoplasia
- Cervical Neoplasm
- Cervical Dysplasia

## Interventions

- **DRUG:** Topical ABI-1968

## Key facts

- **NCT ID:** NCT03697226
- **Lead sponsor:** Antiva Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-21
- **Primary completion:** 2020-05-26
- **Final completion:** 2020-06-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2021-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697226, "Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03697226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*